Related Experiment Videos
[Central hypothyroidism associated with bexarotene therapy].
C Martin1, K Bach-Ngohou, B Perrin
1Service de Biochimie Spécialisée, Unité d'hormonologie et de RIA.
Annales De Biologie Clinique
|July 11, 2006
Summary
Bexarotene Targretin treatment for cutaneous T-cell lymphoma caused central hypothyroidism and hyperlipidemia. These adverse events are manageable with fenofibrate Lipanthyl and high-dose L-thyroxine Lévothyrox.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin lymphoma.
- Bexarotene Targretin is a synthetic retinoid analog targeting the retinoid X receptor (RXR).
Observation:
- A patient with CTCL treated with bexarotene Targretin developed mixed hyperlipidemia.
- The patient also experienced severe central hypothyroidism, indicated by reduced thyroid-stimulating hormone (TSH) and thyroxine levels.
- The pituitary thyreotrope function was specifically affected.
Findings:
- Bexarotene Targretin therapy can induce central hypothyroidism and hyperlipidemia.
- These adverse drug events can be effectively managed.
- Fenofibrate Lipanthyl can manage dyslipidemia.
- High-dose L-thyroxine Lévothyrox is required for central hypothyroidism, necessitating monitoring of serum free thyroxine levels.
Implications:
- Bexarotene Targretin therapy can be continued despite adverse effects.
- Management strategies exist for bexarotene-induced endocrinopathies.
- This case highlights the importance of monitoring thyroid function during bexarotene treatment.